Akkermansia muciniphila-derived pentadecanoic acid enhances oxaliplatin sensitivity in gastric cancer by modulating glycolysis

• DOI: 10.1016/j.phrs.2024.107278
• Publication Date: 2024-06-20T17:19:54Z
• Authors: Qixuan Xu; Jingwang Gao; Ruiyang Zhao; Hanghang Li; Hao Cui; Zhen Yuan; Huiguang Ren; Bo Cao; Bo Wei
• Keywords: Male; 0301 basic medicine; Mice, Inbred BALB C; Antineoplastic Agents; RM1-950; Akkermansia; Gastrointestinal Microbiome; Anti-Bacterial Agents; Oxaliplatin; Mice, Inbred C57BL; Gut dysbiosis; Mice; 03 medical and health sciences; Stomach Neoplasms; Cell Line, Tumor; Animals; Humans; Therapeutics. Pharmacology; Gastric cancer; Pentadecanoic acid; Glycolysis; Akkermansia muciniphila

Accumulating evidence has proved the close association between alterations in gut microbiota and resistance to chemotherapeutic drugs. However, the potential roles of gut microbiota in regulating oxaliplatin sensitivity in gastric cancer (GC) have not been investigated before. We first found that antibiotic treatment diminished the therapeutic efficacy of oxaliplatin in a GC mouse model. Importantly, this effect could be transmitted to germ-free mice via fecal microbiota transplantation, indicating a potential role of gut microbiota modulation in oxaliplatin efficacy. Further, metagenomics data showed that Akkermansia muciniphila (A. muciniphila) ranked first among the bacterial species with decreased relative abundances after antibiotic treatment. Metabolically active A. muciniphila promotes oxaliplatin efficacy. As shown by metabolomics analysis, the metabolic pattern of gut microbiota was disrupted with significantly downregulated levels of pentadecanoic acid (PEA), and the use of PEA significantly promoted oxaliplatin efficacy. Mechanistically, FUBP1 positively regulated aerobic glycolysis of GC cells to hinder the therapeutic efficacy of oxaliplatin. A. muciniphila-derived PEA functioned as an inhibitory factor of glycolysis by directly antagonizing the activity of FUBP1, which potentiated GC responses to oxaliplatin. Our research suggested a key role for intestinal A. muciniphila and its metabolite PEA in promoting oxaliplatin efficacy, thus providing a new perspective for probiotic and prebiotic intervention in GC patients during chemotherapy.